An FOBT, or fecal occult blood test, is a screening test that checks your stool for tiny amounts of blood invisible to the naked eye. “Occult” simply means hidden. The test is used primarily to screen for colorectal cancer and precancerous polyps, since these growths often bleed small amounts into the digestive tract long before symptoms appear. It’s one of the simplest cancer screening tools available: you collect stool samples at home, send them to a lab, and get results without any invasive procedure.
How the Test Detects Blood
There are two main types of FOBT, and they work in fundamentally different ways. The older version, called a guaiac FOBT (gFOBT), uses a chemical reaction. A stool sample is smeared on a card treated with a plant-based compound called guaiac. When a lab technician adds hydrogen peroxide to the card, the iron-containing part of hemoglobin (the protein that carries oxygen in blood) acts as a catalyst and turns the card blue. If there’s no blood, no color change happens.
The newer version, called a fecal immunochemical test (FIT), uses antibodies designed to latch onto human hemoglobin specifically. This distinction matters. Because FIT targets human blood proteins directly, it’s far less likely to react to blood from food you’ve eaten, like a rare steak. FIT has largely replaced the guaiac test in routine screening for this reason, though both are still in use.
Who Should Get Screened and How Often
The U.S. Preventive Services Task Force recommends colorectal cancer screening for all average-risk adults starting at age 45. If you choose stool-based testing as your screening method, the recommended interval is once per year for a high-sensitivity FOBT or FIT. Screening typically continues through age 75, with decisions after that based on individual health and life expectancy.
Annual testing is important because these tests catch blood from a single point in time. A polyp or early cancer may not bleed every day, so repeating the test yearly increases the chance of catching something that one test alone might miss.
How to Collect Your Samples
If your doctor gives you a gFOBT kit, the process takes several days because you need stool samples from three separate bowel movements. The kit includes cards with labeled sections, collection sticks, and a sheet of flushable tissue paper. For each bowel movement, you float the tissue in the toilet bowl, let your stool land on it, then use the stick to smear a thin sample onto area “A” of the card. You take a second sample from a different part of the same stool and smear it on area “B.” Each of the three cards corresponds to a different bowel movement.
Between collections, you store the card in its paper envelope in a cool, dark place (not the refrigerator). After completing all three sections, you let the card dry overnight, then seal it in the foil-lined mailing pouch and either mail it or bring it to your doctor’s office.
FIT kits are simpler. Most require only one or two samples and involve either brushing the surface of your stool in the toilet or using a probe to collect a small amount. The specific steps vary by brand, so follow the instructions in your kit.
Diet and Medication Restrictions
This is where the two test types differ significantly. If you’re using the older guaiac test, certain foods contain natural compounds with the same chemical activity as blood, which can trigger a false positive. Red meat, broccoli, turnips, and horseradish are common culprits. On the other side, vitamin C can actually block the chemical reaction, potentially hiding real blood and causing a false negative. Your doctor will typically ask you to avoid these foods and supplements for a few days before and during sample collection.
Blood-thinning medications like aspirin and warfarin can also affect guaiac test results, not by interfering with the chemistry, but by making your digestive tract more likely to bleed from minor irritation that wouldn’t otherwise cause detectable blood loss.
FIT testing requires none of these dietary restrictions. Because the antibodies in the test react only to human hemoglobin, what you ate the night before won’t affect your results. This is one of the main reasons FIT has become the preferred stool-based screening option.
What a Positive Result Means
A positive FOBT means blood was detected in your stool. It does not mean you have cancer. Many common, noncancerous conditions cause hidden blood in stool: hemorrhoids, stomach ulcers, gastritis, diverticular disease, and inflammatory bowel conditions like Crohn’s disease or ulcerative colitis. Even swallowing blood from a nosebleed can occasionally trigger a positive result on a guaiac test.
The guaiac FOBT detects about 69% of colorectal cancers and roughly 77% of all colorectal growths including polyps. FIT performs similarly for cancer detection, catching around 70% to 75% of cancers. These numbers mean the test will miss some cancers, and it will also flag plenty of people who don’t have cancer at all. The positive predictive value for cancer specifically is low, around 7%, meaning that out of 100 people with a positive guaiac result, roughly 7 will turn out to have colorectal cancer.
The standard next step after any positive result is a colonoscopy. This allows a doctor to visually inspect the entire colon and rectum, identify the source of bleeding, and remove polyps during the same procedure if needed. A positive stool test is not a diagnosis. It’s a signal that a closer look is warranted.
How FOBT Compares to Colonoscopy
Colonoscopy is the most thorough screening tool for colorectal cancer. It examines the full surface of the colon, detects polyps and cancers with very high sensitivity when performed by an experienced doctor, and allows removal of precancerous growths on the spot. A stool test can’t do any of that.
What stool tests offer is accessibility. They’re noninvasive, inexpensive, require no sedation or bowel preparation, and can be done entirely at home. For people who might otherwise skip screening altogether, an annual FIT test is far better than no screening at all. Large, long-running trials have directly established that regular guaiac-based testing reduces colorectal cancer deaths over time. The key is consistency: a single FOBT is a snapshot, but years of annual testing builds a cumulative safety net.
Some newer stool tests, called multitarget stool DNA tests, combine FIT with genetic markers shed by abnormal cells. These have higher sensitivity for early-stage cancer than FIT alone, though they cost more and are done less frequently (every three years). Your choice of screening method depends on your risk level, preferences, and what you’re most likely to follow through on consistently.